Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis.
Czyz A, Romejko-Jarosinska J, Helbig G, Knopinska-Posluszny W, Poplawska L, Piatkowska-Jakubas B, Hawrylecka D, Nasilowska-Adamska B, Dytfeld D, Lojko-Dankowska A, Kopinska A, Boguradzki P, Walewski J, Kyrcz-Krzemien S, Hellmann A, Komarnicki M. Czyz A, et al. Among authors: dytfeld d. Ann Hematol. 2013 Jul;92(7):925-33. doi: 10.1007/s00277-013-1716-2. Epub 2013 Mar 8. Ann Hematol. 2013. PMID: 23471671 Free PMC article.
Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.
Czyz A, Romejko-Jarosinska J, Knopinska-Posluszny W, Nowicki A, Lojko-Dankowska A, Gil L, Dytfeld D, Walewski J, Hellmann A, Komarnicki M. Czyz A, et al. Among authors: dytfeld d. Leuk Lymphoma. 2013 May;54(5):973-8. doi: 10.3109/10428194.2012.734612. Epub 2012 Oct 29. Leuk Lymphoma. 2013. PMID: 23025342
Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Czyz A, Lojko-Dankowska A, Dytfeld D, Nowicki A, Gil L, Matuszak M, Kozlowska-Skrzypczak M, Kazmierczak M, Bembnista E, Komarnicki M. Czyz A, et al. Among authors: dytfeld d. Med Oncol. 2013;30(3):611. doi: 10.1007/s12032-013-0611-y. Epub 2013 May 24. Med Oncol. 2013. PMID: 23702734 Free PMC article.
Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis.
Czyż A, Lojko-Dankowska A, Matuszak M, Dytfeld D, Kaźmierczak M, Komarnicki M. Czyż A, et al. Among authors: dytfeld d. Contemp Oncol (Pozn). 2013;17(2):200-4. doi: 10.5114/wo.2013.34626. Epub 2013 Apr 29. Contemp Oncol (Pozn). 2013. PMID: 23788991 Free PMC article.
Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.
Łuczak M, Kubicki T, Rzetelska Z, Szczepaniak T, Przybyłowicz-Chalecka A, Ratajczak B, Czerwińska-Rybak J, Nowicki A, Joks M, Jakubowiak A, Komarnicki M, Dytfeld D. Łuczak M, et al. Among authors: dytfeld d. Pol Arch Intern Med. 2017 Jun 30;127(6):392-400. doi: 10.20452/pamw.4032. Epub 2017 May 25. Pol Arch Intern Med. 2017. PMID: 28546528 Free article.
48 results